Complex chromosomal aberrations in chronic lymphocytic leukemia are associated with cellular drug and irradiation resistance.
Drug resistance is a major problem in chemotherapy of chronic lymphocytic leukemia (CLL). The genetic basis and molecular pathogenesis of drug resistance in CLL remain poorly understood. Here, we have investigated the association between chromosomal aberrations and cellular resistance of CLL cells against seven drugs, gamma and ultraviolet irradiation. Samples were obtained from 35 patients having a classical form of B-CLL. Chromosomal aberrations were first analyzed by traditional karyotyping improved by using optimized mitogen combinations. DNA sequence copy number changes throughout the genome were next screened by comparative genomic hybridization. Finally, fluorescence in situ hybridization was used to detect trisomy 12 and loss of Rb and deletions at chromosome 11. The cellular sensitivity in vitro was assessed by the reduction of macromolecular protein synthesis measured as incorporation of radioactive L-leucine as an endpoint. The overall analysis disclosed a statistically highly significant difference in cellular drug resistance between patients having at least three aberrations compared with patients with fewer or no aberrations. This strongly indicates that complex rather than simple molecular mechanisms are responsible for the drug and irradiation resistance in CLL. According to published results, complex aberrations are constantly associated with poor prognosis in CLL. We demonstrated here that complex chromosomal aberrations were associated with cellular irradiation and drug resistance, which, on the other hand, may be responsible for the poor clinical outcome in CLL.
Department of Clinical Chemistry, Tampere University Hospital and University of Tampere Medical School, Finland.
T
T
Koski
R
R
Karhu
T
T
Visakorpi
L
L
Vilpo
S
S
Knuutila
J
J
Vilpo
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D002869:Chromosome Aberrations; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics / Q000648:ultrastructure; D002881:Chromosomes, Human, Pair 12; D004273:DNA, Neoplasm / Q000235:genetics; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D005720:Gamma Rays; D017353:Gene Deletion; D016161:Genes, Retinoblastoma; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D008934:Mitogens / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009693:Nucleic Acid Hybridization; D011379:Prognosis; D011836:Radiation Tolerance / Q000235:genetics*; D014314:Trisomy; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000528:radiation effects; D014466:Ultraviolet Rays
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D008934:Mitogens; D009363:Neoplasm Proteins